Journal
MODERN RHEUMATOLOGY
Volume 26, Issue 5, Pages 730-737Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/14397595.2016.1140274
Keywords
Antineutrophil cytoplasmic antibody-associated vasculitis; Eosinophilic granulomatosis with polyangiitis; Granulomatosis with polyangiitis; Inception cohort; Microscopic polyangiitis
Categories
Funding
- Teijin Pharma, Ltd.
- Abbott Japan Co., Ltd.
- Astellas Pharma Inc.
- Bristol-Myers Squibb K.K.
- Chugai Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Janssen Pharmaceutical K.K.
- Mitsubishi Tanabe Pharma Co.
- Santen Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Pfizer Japan Inc.
- Pfizer Inc.
- AbbVie Inc.
- Daiichi Sankyo Co. Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Astellas
- Boehringer-Ingelheim
- Daiichi Sankyo
- Dainippon Sumitomo
- Kyowa Hakko Kirin
- Mochida
- MSD
- Novartis
- Novo Nordisk
- Pfizer
- Takeda
- Tanabe Mitsubishi
- Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan
- Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan
- study group for strategic exploration of drug seeds for ANCA-associated vasculitis and construction of clinical evidence from Japan Agency for Medical Research and development, AMED
Ask authors/readers for more resources
Objective: To compare disease severity classification systems for six-month outcome prediction in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: Patients with newly diagnosed AAV from 53 tertiary institutions were enrolled. Six-month remission, overall survival, and end-stage renal disease (ESRD)-free survival were evaluated. Results: According to the European Vasculitis Study Group (EUVAS)-defined disease severity, the 321 enrolled patients were classified as follows: 14, localized; 71, early systemic; 170, generalized; and 66, severe disease. According to the rapidly progressive glomerulonephritis (RPGN) clinical grading system, the patients were divided as follows: 60, grade I; 178, grade II; 66, grade III; and 12, grade IV. According to the Five-Factor Score (FFS) 2009, 103, 109, and 109 patients had <= 1, 2, and >= 3 points, respectively. No significant difference in remission rates was found in any severity classification. The overall and ESRD-free survival rates significantly differed between grades I/II, III, and IV, regardless of renal involvement. Severe disease was a good predictor of six-month overall and ESRD-free survival. The FFS 2009 was useful to predict six-month ESRD-free survival but not overall survival. Conclusions: The RPGN grading system was more useful to predict six-month overall and ESRD-free survival than the EUVAS-defined severity or FFS 2009.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available